Kisspeptin-10 is the shortest bioactive fragment of an endogenous human hormone that sits upstream of GnRH in the reproductive hormone cascade. It has been given to people in controlled studies, mostly short infusions or single injections in healthy men and in patients with reproductive disorders, and the longest published subcutaneous exposure is 12 days (Yeung 2026). The best-known clinical-outcome trial, a Phase 2 IVF-trigger study with a 95% oocyte maturation rate, used the longer-acting kisspeptin-54 instead. Kisspeptin-10 itself has an even shorter plasma half-life, on the order of minutes.
Ask about Kisspeptin-10 and -54
Research snapshot
| Category | Current information |
|---|---|
| Peptide category | Shortest bioactive fragment of endogenous human kisspeptin, upstream regulator of GnRH |
| Primary research interest | Reproductive/hormonal axis stimulation (LH, testosterone); IVF oocyte maturation trigger (mostly studied via the related kisspeptin-54) |
| Highest available evidence | Tier 1: published human studies of kisspeptin-10 itself (randomized, placebo-controlled, up to 12 days of subcutaneous exposure in 15 healthy men); the larger Phase 2 IVF trigger trial used kisspeptin-54, not kisspeptin-10 |
| Human research available | Yes. Healthy-volunteer and patient studies have given kisspeptin-10 by IV bolus, IV infusion and subcutaneous infusion; registered trials of subcutaneous kisspeptin-10 in reproductive disorders are completed or recruiting; the larger IVF outcome trial used kisspeptin-54 |
| Development status | Not advanced as an approved drug; investigational academic use; kisspeptin-54 studied as an investigational IVF trigger |
| Regulatory status | Not approved for any use, in either form. Listed in FDA 503A Category 2 (significant safety risks) on the page dated May 14, 2026 |
Technical identity
| Technical property | Information |
|---|---|
| Primary name | Kisspeptin-10 |
| Alternative names | Metastin (45-54), KP-10 |
| Amino-acid length | 10 (shortest fragment retaining full receptor-binding activity of the parent hormone) |
| Molecular formula | C63H83N17O14 |
| Molecular weight | ≈1302.4 g/mol |
| CAS Registry Number | 374675-21-5 |
| PubChem CID | Not reliably established (a candidate ID could not be confirmed against PubChem) |
| Peptide class | Kisspeptin receptor (KISS1R/GPR54) agonist |
| Primary biological target | Kisspeptin receptor (KISS1R), upstream of GnRH neurons |
| Developer / originator | Endogenous human hormone fragment; studied academically (Imperial College London, Massachusetts General Hospital) |
| Development status | Not an approved drug; related kisspeptin-54 studied investigationally as an IVF trigger |
What it is
Kisspeptin is an endogenous human peptide hormone that sits upstream of GnRH in the reproductive hormone cascade, stimulating the hypothalamus to release GnRH, which in turn drives LH and FSH secretion. The full-length hormone (kisspeptin-54) is cleaved into shorter fragments, including kisspeptin-10, the shortest fragment retaining full receptor-binding activity. Kisspeptin-10 has an extremely short plasma half-life, on the order of a few minutes, shorter than kisspeptin-54’s.
What dosage information circulates?
Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.
| Reported use or research objective | Route reported | Amount reported | Frequency reported | Reported duration | Evidence or source category |
|---|---|---|---|---|---|
| Reproductive axis, healthy men (kisspeptin-10) | Intravenous bolus | 0.3 mcg/kg; 1 mcg/kg | Single dose | Not applicable | Published human clinical trial (Skorupskaite 2017; Ullah 2018) |
| Acute dose-response, healthy men (kisspeptin-10) | Subcutaneous infusion | 1.25 to 10.0 nmol/kg/h | Continuous for one 8-hour session | 8 hours | Published human clinical trial (Yeung 2026) |
| Chronic stimulation, healthy men (kisspeptin-10) | Subcutaneous infusion | 150 nmol/h | Daily, 8 hours on and 16 hours off | 12 days | Published human clinical trial (Yeung 2026) |
| Continuous exposure, healthy men (kisspeptin-10) | Subcutaneous infusion; intravenous infusion | 180 nmol/h subcutaneous; 12.5 mcg/kg/h intravenous | Continuous | 5 days subcutaneous; 24 hours intravenous (3 men) | Published human clinical trial (Yeung 2026; Naveed 2026) |
| IVF oocyte maturation trigger (kisspeptin-54, not kisspeptin-10) | Single injection, clinic-administered | 3.2 to 12.8 nmol/kg | Single dose | Not applicable | Published human Phase 2 RCT (Abbara 2015) |
| Reproductive hormone support, as circulated online | Subcutaneous | 100 to 200 mcg | 1 to 3 times per week | 4 to 8 weeks | Community reported (Peptide Protocol Wiki); origin unclear |
| Daily low-dose schedule, as circulated online | Subcutaneous | 100 mcg | Once daily | 4 to 8 weeks | Community reported (Peptide Protocol Wiki); origin unclear |
Every figure from a controlled study above is a supervised infusion or a single injection dosed by body weight or by pump rate, in micrograms or nanomoles. None is a fixed-microgram injection that a person gives themselves. The units are not interchangeable: nmol/kg, mcg/kg and nmol/h describe different things, and no study has converted any of them into a flat self-injection amount.
The community figures, mostly 100 to 200 micrograms under the skin one to three times a week, appear on community and educational pages that cite forums and each other rather than a primary study. Peptide Dossier reports a similar 100 to 200 microgram schedule two to three times weekly for 4 to 6 weeks and says it is not validated by the studies it cites. This is widely repeated online, but its original source could not be verified. An earlier version of this page listed 100 to 250 micrograms once or twice daily; no source for that schedule was found, so it was removed.
The closest published match to repeated dosing is the 2026 subcutaneous infusion study, which delivered 150 nanomoles an hour for 8 hours a day with a 16-hour break. That was a pump, not an injection. When the infusion ran around the clock for 5 days, the rise in LH and FSH faded back to placebo levels while testosterone stayed raised. Whether any injection schedule behaves like either pattern has not been tested.
Potential benefits and research applications
Oocyte maturation trigger in IVF, demonstrated with kisspeptin-54, not kisspeptin-10
A Phase 2 randomized trial in 60 women at high risk of ovarian hyperstimulation syndrome used kisspeptin-54 as an alternative trigger to hCG or GnRH agonist, achieving oocyte maturation in 95% of women and live birth rates up to 62% at the optimal dose, with no cases of moderate, severe or critical OHSS.
Evidence: has been shown in a randomized, controlled human Phase 2 trial (Tier 1, published human clinical evidence) for kisspeptin-54; has not been established for kisspeptin-10 specifically, which was not the compound used in this trial.
Stimulating the reproductive axis (LH, testosterone), the effect actually studied using kisspeptin-10
Earlier, smaller mechanistic dose-response and bolus-injection studies used kisspeptin-10 specifically and found it raises LH and testosterone in men and stimulates the reproductive axis in both sexes.
Evidence: has been shown in human mechanistic studies (Tier 1-2, published human clinical evidence, smaller and less clinically outcome-focused than the kisspeptin-54 IVF trial); has not been established as a treatment for any specific reproductive or hormonal condition.
General reproductive and hormonal support, the claim behind circulating self-injection use, tested in neither form for that purpose
Kisspeptin-10 is marketed and self-administered for general reproductive and hormonal support. No trial reviewed for this entry, of kisspeptin-10 or kisspeptin-54, tested a periodic self-injected “reproductive health” protocol as an outcome.
Evidence: has been reported anecdotally (Tier 6, community-reported information); has not been established by any trial of either form for this general use.
The human trial record, and which form was actually used
This is important to state precisely: most of the substantial human trial work on kisspeptin, run mainly by groups at Imperial College London and Massachusetts General Hospital, used kisspeptin-54, not kisspeptin-10, specifically because the longer fragment’s somewhat longer half-life makes it more practical to dose.
A Phase 2, multi-dose, open-label, randomized trial in 60 women at high risk of ovarian hyperstimulation syndrome (OHSS) during IVF used a single injection of kisspeptin-54, at doses from 3.2 to 12.8 nmol/kg, to trigger oocyte maturation as an alternative to hCG or GnRH agonist triggers; oocyte maturation occurred in 95% of women, live birth rates reached 45% overall (62% at the 9.6 nmol/kg dose), and no woman developed moderate, severe or critical OHSS.
A separate study in eight healthy postmenopausal women used a continuous 24-hour kisspeptin-54 infusion (12.5 mcg/kg/h) to probe how circulating estradiol modulates kisspeptin-stimulated LH pulsatility, finding that postmenopausal women were largely resistant to kisspeptin’s stimulatory effect unless given estradiol replacement.
Kisspeptin-10 specifically has been used in earlier, smaller mechanistic dose-response and bolus-injection studies establishing that it raises LH and testosterone in men and stimulates the reproductive axis in both sexes, but the larger, better-powered trials with clinical outcomes (the IVF trigger trial, the postmenopausal infusion study) used kisspeptin-54.
What the newest kisspeptin-10 studies show
Yeung 2026 (Imperial College London, European Journal of Endocrinology) is the most relevant study for anyone asking about repeated subcutaneous kisspeptin-10. It was randomized, single-blinded and placebo-controlled, with 15 healthy men recruited across three studies. Acute subcutaneous infusions of 1.25 to 10.0 nmol/kg/h for 8 hours raised LH, FSH and testosterone in a dose-dependent way. Running the infusion continuously at 180 nmol/h for 5 days kept testosterone up but let LH and FSH fall back to placebo levels. Giving 150 nmol/h for 8 hours a day, with 16 hours off, for 12 days kept LH elevated (mean rise +1.68 on day 1 and +1.14 on day 12), and a 1 nmol/kg bolus after day 12 still raised gonadotropins, so the receptor still responded. In plain terms, breaks between exposures preserved the response and round-the-clock exposure did not. Limits: small numbers, healthy men only, pump delivery, 12 days.
Naveed 2026 (Massachusetts General Hospital, Hormones) gave three healthy men kisspeptin-10 as a 12.5 mcg/kg/h intravenous infusion for 24 hours (NCT01438073). LH rose 5 to 8 fold, peaking 12 to 20 hours in, and then declined by 13 to 47% from its peak even though the infusion continued. FSH and testosterone rose modestly. Three men is a very small sample, but the fade matches the 5-day result above.
Older single-dose studies used an intravenous bolus. Ullah 2018 gave 1 mcg/kg to healthy men in three age groups: LH rose in all groups, while testosterone rose significantly only in the younger adults. Skorupskaite 2017 used 0.3 mcg/kg as a probe in 6 healthy men during an NK3 receptor antagonist study, and LH still responded.
Registered trials of kisspeptin-10 in patients with reproductive disorders are listed by the ClinicalTrials.gov interventions “kisspeptin 112-121”, the residue numbering for kisspeptin-10: NCT05633966 (Phase 1, subcutaneous, completed, 13 enrolled), NCT04648969 (Phase 2, prolonged pulsatile dosing in hypogonadotropic hypogonadism, completed, 18 enrolled) and NCT05896293 (Phase 2, subcutaneous, recruiting, 36 planned). No results were posted for the first two at the time of checking.
What is not established
Whether findings from kisspeptin-54 trials, including the IVF trigger and postmenopausal infusion studies, transfer directly to kisspeptin-10, given the shorter fragment’s even shorter half-life and the studies’ use of continuous infusion or single supervised injections rather than a periodic self-administered subcutaneous shot.
Any established dose, frequency or indication for kisspeptin-10 specifically outside a supervised research or fertility-clinic setting. No trial reviewed for this entry tested a general “reproductive health” self-injection protocol.
What circulates E5
| Reported use | Route | Amount reported | Frequency | Reported length |
|---|---|---|---|---|
| Reproductive/hormonal support, general | Subcutaneous | 100 to 250 mcg per dose | Once or twice daily | Ongoing |
Community pages report 100 to 200 micrograms subcutaneously one to three times a week for 4 to 8 weeks (Peptide Protocol Wiki). They cite forums, not a primary study. Controlled human studies of kisspeptin-10 used intravenous boluses of 0.3 to 1 microgram per kilogram, intravenous infusion, and subcutaneous pump infusions for up to 12 days, not fixed-dose self-injection.
Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.
Side effects, risks, and limitations
The studies above are short and small, and the abstracts reviewed for this update do not give adverse-event tables, so no safety profile for kisspeptin-10 self-injection can be stated. The longest published exposure is 12 days of subcutaneous infusion in 15 healthy men (Yeung 2026). The clear finding is pharmacological: kisspeptin-10 raises LH, FSH and testosterone, and continuous exposure made the gonadotropin response fade. The effects of repeated dosing on fertility, other hormones or long-term health have not been studied.
Product identity is a separate unknown. No analysis of kisspeptin-10 vials sold for self-use was identified in this review, so purity, peptide content and sterility cannot be assumed.
Regulatory and developmental status
Kisspeptin-10 is not an approved drug for any use in the sources checked. FDA’s 503A bulk drug substances page, dated May 14, 2026 and read on October 8, 2026, lists Kisspeptin-10 in Category 2, the list of nominated substances that raise significant safety risks. The listing itself gives no kisspeptin-specific reasoning and refers readers to a separate FDA summary page that was not read for this update. It was not among the peptides removed from Category 2 in April 2026. Approval status outside the United States was not checked. Development remains academic: the registered trials above are run by university hospitals, and a pharmaceutical kisspeptin analogue (TAK-448, Takeda) was a different molecule whose Phase 2a trial NCT02369796 was terminated.
Frequently asked questions
What is kisspeptin-10?
Kisspeptin-10 is the shortest bioactive fragment of an endogenous human hormone that stimulates GnRH release upstream in the reproductive hormone cascade.
How does kisspeptin-10 work?
It stimulates the hypothalamus to release GnRH, which drives LH and FSH secretion, activating the reproductive hormone axis.
What dosage has been studied in humans?
Controlled studies of kisspeptin-10 used single intravenous boluses of 0.3 to 1 microgram per kilogram, a 24-hour intravenous infusion of 12.5 micrograms per kilogram per hour, and subcutaneous pump infusions of 1.25 to 10.0 nanomoles per kilogram per hour for 8 hours, 180 nanomoles per hour for 5 days, or 150 nanomoles per hour for 8 hours a day over 12 days. The IVF trigger trial used kisspeptin-54 at 3.2 to 12.8 nanomoles per kilogram.
What dosage commonly circulates online?
Community pages most often report 100 to 200 micrograms subcutaneously one to three times a week for 4 to 8 weeks, with a 100 microgram daily schedule also described (Peptide Protocol Wiki). These pages cite forums rather than a primary study: widely repeated online, but the original source could not be verified. No controlled trial gave kisspeptin-10 as a fixed-dose self-injection.
Has kisspeptin-10 been studied in humans?
Yes. Studies in healthy men and in patients with reproductive disorders have given kisspeptin-10 by IV bolus, IV infusion and subcutaneous infusion, the longest for 12 days (Yeung 2026). Larger clinical-outcome trials, including the IVF trigger trial, used kisspeptin-54.
Is kisspeptin-10 approved for use?
No. It is not approved as a standalone drug. Kisspeptin-54 has been studied as an investigational IVF trigger, but neither form has reached approval. FDA lists kisspeptin-10 in 503A Category 2, substances that raise significant safety risks (page dated May 14, 2026).
What routes of administration are reported?
Controlled trials used continuous IV infusion or single clinic-administered injections of kisspeptin-54. Community-reported use of kisspeptin-10 describes subcutaneous self-injection.
Can I use kisspeptin-10 findings to predict kisspeptin-54 effects, or vice versa?
This has not been established. The two fragments have different half-lives, and most large clinical-outcome trials tested kisspeptin-54, not kisspeptin-10, so findings should not be assumed to transfer between them.
What side effects have been reported?
The IVF trigger trial using kisspeptin-54 reported no cases of moderate, severe or critical OHSS. No side-effect profile for kisspeptin-10 self-injection has been established. The longest published exposure is 12 days of subcutaneous infusion in 15 healthy men (Yeung 2026), and adverse-event tables were not available in the abstracts reviewed.
What remains unknown about kisspeptin-10?
Whether findings from kisspeptin-54 trials transfer to kisspeptin-10, given its shorter half-life, and any established dose, frequency or indication for kisspeptin-10 specifically outside a supervised research or fertility-clinic setting.
Bottom line
Kisspeptin-10 belongs to a hormone family with real human trial data, but the best-known clinical outcome trial, the IVF trigger study, used kisspeptin-54. Kisspeptin-10 itself has been given to people in short controlled studies that raised LH, FSH and testosterone in healthy men, the longest published subcutaneous exposure is 12 days, and continuous exposure made the response fade. The weekly self-injection schedules circulating online (100 to 200 micrograms) have no controlled trial behind them and no traceable original source. Kisspeptin-10 is not approved in the sources checked and sits in FDA’s 503A Category 2 as of the page dated May 14, 2026.
Sources
- Abbara A, et al. Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy. J Clin Endocrinol Metab 2015;100(9):3322-31. Human Phase 2 RCT, n=60, kisspeptin-54 (not kisspeptin-10). PMID 26192876
- Lippincott MF, et al. Continuous Kisspeptin Administration in Postmenopausal Women: Impact of Estradiol on Luteinizing Hormone Secretion. J Clin Endocrinol Metab 2017;102(6):2091-2099. Human, n=8, continuous kisspeptin-54 infusion (not kisspeptin-10). PMID 28368443
- Naveed A, et al. Dynamic modulation of LH secretion by continuous kisspeptin infusion in healthy men. Hormones (Athens) 2026. Three healthy men, IV kisspeptin-10 12.5 mcg/kg/h for 24 h; LH rose 5 to 8 fold then declined 13 to 47% from peak. Registered NCT01438073. PMID 42230485
- Yeung AC, et al. Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men. Eur J Endocrinol 2026;195(2):206-216. Randomized, single-blinded, placebo-controlled, 15 healthy men; SC kisspeptin-10 acute dose-response 1.25 to 10.0 nmol/kg/h for 8 h, continuous 180 nmol/h for 5 days, and 150 nmol/h for 8 h daily for 12 days. PMID 42549827
- US Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A. Page dated May 14, 2026, read October 8, 2026. Kisspeptin-10 listed in Category 2, substances that raise significant safety risks. FDA media 94155
- Seminara SB, Massachusetts General Hospital. Kisspeptin administration subcutaneously to patients with reproductive disorders. Phase 1, completed, 13 enrolled, intervention kisspeptin 112-121 (kisspeptin-10). No results posted at time of check. NCT05633966
- Ullah H, et al. Age-dependent changes in the reproductive axis responsiveness to kisspeptin-10 administration in healthy men. Andrologia 2019;51(4):e13219. Single IV bolus kisspeptin-10 1 mcg/kg in healthy men of three age groups. PMID 30590872
- Skorupskaite K, et al. Neurokinin 3 receptor antagonism decreases gonadotropin and testosterone secretion in healthy men. Clin Endocrinol 2017;87(6):748-756. Kisspeptin-10 0.3 mcg/kg IV bolus given as a probe in 6 healthy men. PMID 28802064
- Educational site comparing studied kisspeptin doses with circulating ones; reports a circulating subcutaneous protocol of 100 to 200 mcg 2 to 3 times weekly for 4 to 6 weeks and states it is not validated by the studies cited. Read October 8, 2026. peptidedossier.com
- Community page summarizing forum and self-experimenter reports for subcutaneous kisspeptin-10 (100 to 200 mcg 1 to 3 times weekly for 4 to 8 weeks; 100 mcg daily; 50 to 100 mcg multiple times daily for 2 to 4 weeks). Cites Reddit and other secondary sites, no primary study. Read October 8, 2026. peptideprotocolwiki.com
- Seminara SB, Massachusetts General Hospital. Prolonged pulsatile kisspeptin administration in hypogonadotropic hypogonadism. Phase 2, completed, 18 enrolled, intervention kisspeptin 112-121 (kisspeptin-10) and GnRH. No results posted at time of check. NCT04648969
Live registry status
These are the registered trials this page cites, pulled from ClinicalTrials.gov and refreshed automatically. Status and dates are what the registry currently shows. Listing a trial here does not mean it produced a positive result.
| Trial | Phase | Status | Sponsor | Enrolled | Primary completion | Registry updated |
|---|---|---|---|---|---|---|
| Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism NCT04648969 | Phase 2 | Completed | Stephanie B. Seminara, MD | 18 | Aug 31, 2025 | Aug 26, 2026 |
| Kisspeptin Administration Subcutaneously to Patients With IHH NCT05896293 | Phase 2 | Recruiting | Stephanie B. Seminara, MD | 36 | May 2028 | Jul 13, 2026 |
| Kisspeptin Administration Subcutaneously to Patients With Reproductive Disorders NCT05633966 | Phase 1 | Completed | Stephanie B. Seminara, MD | 13 | Aug 31, 2025 | Oct 3, 2025 |
| Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling NCT01438073 | Phase 1 | Completed | Massachusetts General Hospital | 96 | Apr 2016 | Jul 11, 2022 |
| A Phase 2a Pharmacodynamic Study of TAK-448 in Participants With Hypogonadotropic Hypogonadism NCT02369796 | Phase 2 | Terminated | Takeda | 15 | Oct 2015 | Mar 31, 2017 |
Compare Kisspeptin-10 with related compounds
Research area: Sexual health and melanocortin.